Ganciclovir Shortage: What Providers and Prescribers Need to Know in 2026

Ganciclovir remains a cornerstone antiviral for the management of cytomegalovirus (CMV) disease in immunocompromised patients. Despite not being in an active FDA-declared shortage as of early 2026, clinicians in infectious disease, transplant medicine, and hospital pharmacy continue to encounter localized access barriers — particularly for the IV formulation. This guide provides a clinically actionable overview for prescribers.

Current Supply Landscape

Ganciclovir IV injection (500 mg lyophilized powder for reconstitution) is currently available from a limited number of generic manufacturers, including Fresenius Kabi USA. The drug is not in active FDA shortage as of 2026, but supply chain resilience is thin. The limited manufacturer base, low volume relative to manufacturing complexity, and specialty distribution channels make ganciclovir IV persistently vulnerable to localized shortfalls.

Ganciclovir ophthalmic gel 0.15% (Zirgan, Bausch & Lomb) is a brand-name-only product distributed through retail and specialty pharmacy channels. Its high retail cost (over $500 per tube) means not all pharmacies stock it routinely. Supply is generally adequate but access barriers due to cost and stocking are common.

Clinical Impact of Access Delays

For providers, delays in securing ganciclovir for inpatient or outpatient infusion can have significant clinical consequences:

CMV retinitis: Any delay in induction therapy risks disease progression to permanent vision loss. The induction regimen (5 mg/kg IV q12h x 14-21 days) must start promptly.

Post-transplant prophylaxis: Gaps in CMV prophylaxis increase the risk of CMV viremia and end-organ disease, particularly CMV pneumonitis, hepatitis, and colitis — each of which can threaten graft and patient survival.

Inpatient IV-to-oral transitions: For patients being bridged from IV ganciclovir to oral valganciclovir, supply gaps at the point of discharge can create dangerous coverage lapses.

Therapeutic Alternatives for Clinical Substitution

When ganciclovir IV is unavailable or delayed, the following therapeutic substitutions are evidence-based and widely accepted in practice:

Valganciclovir (Valcyte): For patients who can absorb oral medications, valganciclovir 900 mg PO BID (induction) or 900 mg PO QD (maintenance) achieves systemic ganciclovir exposures comparable to IV ganciclovir 5 mg/kg. This is the most practical substitution for most outpatient and step-down scenarios.

Foscarnet (Foscavir): Reserved for ganciclovir-resistant CMV or patients with severe, refractory myelosuppression. Dosing is 60 mg/kg IV q8h or 90 mg/kg IV q12h for induction. Requires aggressive IV hydration and close electrolyte monitoring.

Letermovir (Prevymis): Approved for CMV prophylaxis in allogeneic HSCT recipients (480 mg PO or IV QD with or without cyclosporin dose adjustment). Not indicated for CMV treatment or solid organ transplant.

Cidofovir: Second-line IV option for treatment-refractory or resistant CMV retinitis. Significant nephrotoxicity risk requires probenecid pretreatment and IV hydration.

Practical Steps for Managing Supply Gaps

Coordinate with hospital pharmacy proactively. For scheduled transplants, ensure ganciclovir stock is confirmed before the procedure — do not wait until post-operative day 1.

Evaluate IV-to-oral transitions early. For clinically stable patients receiving IV ganciclovir induction who have adequate oral absorption, transitioning to valganciclovir at day 14-21 is standard practice and reduces dependency on IV supply.

Establish preferred vendor relationships. Work with your institution's GPO or pharmacy buyer to prioritize ganciclovir IV restocking and identify backup suppliers before a shortage occurs.

Help your patients use medfinder for outpatient supply. For patients who are obtaining medication through a retail or specialty pharmacy after discharge, medfinder's pharmacy location service can identify which pharmacies near the patient currently have ganciclovir in stock, reducing treatment gaps.

Resistance Considerations

Clinicians managing patients with prolonged or repeated ganciclovir exposure should maintain a low threshold for suspecting CMV resistance, particularly if viremia fails to respond after 2-3 weeks of adequate therapy. CMV UL97 mutations (conferring ganciclovir resistance) are most common in patients with prolonged drug exposure and high viral loads. UL97 and UL54 genotyping should be considered in patients with apparent treatment failure.

Key Monitoring Parameters

CBC with differential (at least weekly during induction; biweekly during maintenance) — ganciclovir causes myelosuppression in >20% of patients

Serum creatinine and eGFR — dose-adjust based on CrCl at every treatment cycle

CMV viral load (PCR) — quantitative monitoring guides treatment duration and response assessment

Ophthalmology follow-up for CMV retinitis patients — ganciclovir does not cure CMV and retinal progression can continue even during therapy

For guidance on helping your patients locate ganciclovir at outpatient pharmacies, see our detailed provider guide: How to Help Your Patients Find Ganciclovir in Stock.